Harmony Biosciences (HRMY) Files Mixed Shelf
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Harmony Biosciences (HRMY) Tops Q3 EPS by 22c
November 9, 2021 7:32 AM ESTHarmony Biosciences (NASDAQ: HRMY) reported Q3 EPS of $0.51, $0.22 better than the analyst estimate of $0.29. Revenue for the quarter came in at $80.7 million versus the consensus estimate of $80.92 million.
For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.
... More